Business

Vertex CF drug cleared in Australia

Kalydeco’s the first drug for the underlying cause of CF in people with a particular mutation.

Kalydeco’s the first drug for the underlying cause of CF in people with a particular mutation.

Advertisement

Cambridge-based Vertex Pharmaceuticals Inc.’s Kalydeco drug for cystic fibrosis was approved by Australian regulators. Kalydeco, cleared by US regulators in February 2012, targets the cause of the disease in about 4 percent of the US patient population — those with a specific genetic mutation — helping them produce mucus to absorb and digest food. Life-threatening CF affects about 70,000 people worldwide. In April, investors bid up Vertex shares to a record high after clinical data appeared to dramatically improve the prospects of Vertex’s plan to build a portfolio of CF drugs.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
We hope you've enjoyed your free articles.
Continue reading by subscribing to Globe.com for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com